Related Experiment Video

Updated: Aug 17, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Management of patients co-infected with hepatitis B virus and HIV

Marina Núñez1, Vincent Soriano

  • 1Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain. m_nunez_g@hotmail.com

The Lancet. Infectious Diseases
|May 28, 2005
PubMed

Insights

Managing chronic hepatitis B virus (HBV) infection with HIV co-infection requires careful drug selection. Tenofovir and emtricitabine offer broad antiviral activity against HBV in co-infected patients.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Chronic hepatitis B virus (HBV) infection management is complex in patients with human immunodeficiency virus (HIV) co-infection.
  • Therapeutic strategies must address both viral infections simultaneously.

Purpose of the Study:

  • To review current therapeutic options for chronic HBV infection in the context of HIV co-infection.
  • To highlight the role of specific antiviral drugs in managing HBV/HIV co-infected patients.

Main Methods:

  • Review of approved drugs for chronic HBV infection.
  • Discussion of antiviral properties and resistance profiles of nucleoside and nucleotide analogues.
  • Consideration of interferon-based therapies.

Main Results:

  • Tenofovir and emtricitabine possess dual antiviral activity, expanding treatment options for HBV/HIV co-infected individuals.
  • Nucleotide analogues (adefovir, tenofovir) offer a higher genetic barrier to resistance than nucleoside analogues (lamivudine, emtricitabine).
  • Absence of cross-resistance between nucleoside and nucleotide analogues facilitates salvage and combination therapies.

Conclusions:

  • Pegylated interferon alfa shows promise for HBV/HIV co-infected patients, despite generally poorer responses compared to HIV-negative individuals.
  • Combination therapy and salvage options are available due to distinct resistance profiles of different drug classes.
  • Careful consideration of drug interactions and resistance is crucial for effective HBV/HIV co-infection management.

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...